MCID: TCL004
MIFTS: 53

T-Cell Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for T-Cell Leukemia

MalaCards integrated aliases for T-Cell Leukemia:

Name: T-Cell Leukemia 12 15 17
Leukemia, T-Cell 45 74
Leukemia T-Cell 56

Classifications:



External Ids:

Disease Ontology 12 DOID:715
MeSH 45 D015458
UMLS 74 C0023492

Summaries for T-Cell Leukemia

MalaCards based summary : T-Cell Leukemia, also known as leukemia, t-cell, is related to acute t cell leukemia and leukemia. An important gene associated with T-Cell Leukemia is MIR19B2 (MicroRNA 19b-2), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Human T-cell leukemia virus 1 infection. The drugs Prednisone and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and b cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for T-Cell Leukemia

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to T-Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 257)
# Related Disease Score Top Affiliating Genes
1 acute t cell leukemia 34.3 LMO1 TAL1 TCL6 TLX1 TLX3
2 leukemia 32.6 GAS5 TAL1 TCL1A TCTA TLX1 TLX3
3 lymphoma 32.1 GAS5 TCL1A TCL1B TCL6
4 precursor t-cell acute lymphoblastic leukemia 30.5 LMO1 TAL1 TCL1A TLX1 TLX3
5 acute lymphocytic leukemia 30.5 IL2 TAL1 TLX3
6 adult t-cell leukemia 12.9
7 human t-cell leukemia virus type 1 12.7
8 human t-cell leukemia virus type 2 12.7
9 pediatric t-cell leukemia 12.5
10 human t-cell leukemia virus type 3 12.5
11 leukemia, t-cell, chronic 11.8
12 t-cell prolymphocytic leukemia 11.7
13 t-cell adult acute lymphocytic leukemia 11.7
14 htlv-1 associated myelopathy/tropical spastic paraparesis 11.7
15 leukemia, acute lymphoblastic 11.7
16 myelopathy, htlv-1-associated 11.6
17 tropical spastic paraparesis 11.6
18 netherton syndrome 11.3
19 t-cell childhood acute lymphocytic leukemia 11.3
20 glut1 deficiency syndrome 1 11.2
21 lymphoid leukemia 11.2
22 retrovirus-associated myelopathy 11.2
23 hepatosplenic t-cell lymphoma 11.0
24 chronic interstitial cystitis 10.8
25 alcoholic hepatitis 10.7
26 follicular lymphoma 10.7
27 agammaglobulinemia 10.7
28 spastic paraparesis 10.6
29 hematopoietic stem cell transplantation 10.6
30 human immunodeficiency virus type 1 10.5
31 hepatitis 10.4
32 lymphocytic leukemia 10.4
33 mycosis fungoides 10.4
34 arthritis 10.4
35 cutaneous t cell lymphoma 10.4
36 acquired immunodeficiency syndrome 10.3
37 rheumatoid arthritis 10.3
38 pneumonia 10.3
39 sarcoma 10.2
40 hairy cell leukemia 10.2
41 cervicitis 10.2 IL2 IL2RA
42 leukemia, chronic lymphocytic 2 10.2
43 leukemia, chronic lymphocytic 10.2
44 acute leukemia 10.2
45 hepatitis b 10.2
46 hepatitis c 10.2
47 dermatitis 10.2
48 scabies 10.2
49 leukemia, b-cell, chronic 10.2
50 immunodeficiency 18 10.2 LMO1 TAL1

Graphical network of the top 20 diseases related to T-Cell Leukemia:



Diseases related to T-Cell Leukemia

Symptoms & Phenotypes for T-Cell Leukemia

GenomeRNAi Phenotypes related to T-Cell Leukemia according to GeneCards Suite gene sharing:

27 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.9 ATF4 TAL1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.9 ATF4 IL2RA TAL1 TLX1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.9 ATF4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.9 IL2RA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.9 IL2RA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.9 IL2RA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.9 TLX1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.9 TAL1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.9 ATF4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.9 IL2RA TAL1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.9 IL2RA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.9 IL2RA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.9 IL2RA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.9 ATF4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.9 TLX1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.9 IL2RA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.9 IL2RA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.9 IL2RA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.9 TAL1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.9 TLX1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.9 IL2RA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.9 IL2RA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.9 IL2RA TAL1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.9 IL2RA TAL1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.9 ATF4
26 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.9 ATF4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.9 ATF4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.9 TAL1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.9 TAL1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.9 IL2RA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.9 TLX1

Drugs & Therapeutics for T-Cell Leukemia

Drugs for T-Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 390)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
2
Ifosfamide Approved Phase 4,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
3
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
4
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
6
Epirubicin Approved Phase 4,Phase 2 56420-45-2 41867
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1177-87-3
9
Cisplatin Approved Phase 4,Phase 2,Phase 1 15663-27-1 2767 441203 84093
10
Gemcitabine Approved Phase 4,Phase 2,Phase 1 95058-81-4 60750
11
Zidovudine Approved Phase 4,Phase 2 30516-87-1 35370
12
Peginterferon alfa-2b Approved Phase 4,Phase 2 215647-85-1, 99210-65-8
13
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
26 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31
Isophosphamide mustard Phase 4,Phase 2,Phase 1,Early Phase 1 0
32 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Anti-HIV Agents Phase 4,Phase 2,Phase 1,Not Applicable
36 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1,Not Applicable
38 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Not Applicable
39 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 GABA Agents Phase 4,Phase 1
42 Anticonvulsants Phase 4,Phase 1
43 Psychotropic Drugs Phase 4,Phase 3,Not Applicable
44 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Not Applicable
45 Interferon alpha-2 Phase 4,Phase 2,Phase 1
46 Tranquilizing Agents Phase 4,Phase 3,Not Applicable
47 interferons Phase 4,Phase 2,Phase 1
48 Interferon-alpha Phase 4,Phase 2,Phase 1
49 Antimanic Agents Phase 4
50
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821

Interventional clinical trials:

(show top 50) (show all 352)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
3 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
4 Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma Terminated NCT00854581 Phase 4 Valproic Acid;Zidovudine
5 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
9 A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL) Completed NCT00145002 Phase 3 VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
10 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
13 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
14 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
17 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
18 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
19 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
20 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
21 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
22 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
23 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
24 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
25 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
26 Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL Recruiting NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
27 Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
28 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
29 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
30 High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
31 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
32 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
33 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
34 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
35 Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma Unknown status NCT00003885 Phase 2 arsenic trioxide
36 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
37 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
38 KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Completed NCT01626664 Phase 2 Pralatrexate;gemcitabine plus oxaliplatin;DHAP
39 A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma Completed NCT01724177 Phase 2 Lenalidomide
40 Lenalidomide in HTLV-1 Adult T-Cell Leukemia Completed NCT01274533 Phase 2 Lenalidomide
41 Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma Completed NCT00920790 Phase 2
42 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Completed NCT00061048 Phase 2
43 Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia Completed NCT00095381 Phase 2 forodesine hydrochloride (BCX-1777)
44 Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia Completed NCT00117845 Phase 2
45 A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Completed NCT01378871 Phase 2 IMTOX-25
46 Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 Completed NCT01173887 Phase 2 VCAP/AMP/VECP(mLSG15)
47 Anti-Tac for Treatment of Leukemia Completed NCT00001941 Phase 1, Phase 2
48 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2 Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
49 RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma Completed NCT00081874 Phase 1, Phase 2 RAD001
50 Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma Completed NCT00041327 Phase 2 Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine

Search NIH Clinical Center for T-Cell Leukemia

Cochrane evidence based reviews: leukemia, t-cell

Genetic Tests for T-Cell Leukemia

Anatomical Context for T-Cell Leukemia

MalaCards organs/tissues related to T-Cell Leukemia:

42
T Cells, Bone Marrow, B Cells, Skin, Myeloid, Kidney, Colon

Publications for T-Cell Leukemia

Articles related to T-Cell Leukemia:

(show top 50) (show all 3513)
# Title Authors Year
1
Appropriate radiation dose for symptomatic relief and local control in patients with adult T cell leukemia/lymphoma. ( 30124892 )
2019
2
The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation. ( 30171618 )
2019
3
Direct-Injection Electron Ionization-Mass Spectrometry Metabolomics Method for Analyzing Blueberry Leaf Metabolites That Inhibit Adult T-cell Leukemia Proliferation. ( 30212923 )
2019
4
Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma. ( 30264165 )
2019
5
Epstein-Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution. ( 30368656 )
2019
6
Clinical and histopathological significance of PD-1 expression in cutaneous lesions of adult T-cell leukemia-lymphoma. ( 30385085 )
2019
7
Thoracic manifestations of adult T-cell leukemia/lymphoma on chest CT: difference between clinical subtypes. ( 30582570 )
2019
8
Adult T-Cell Leukemia-Lymphoma. ( 30596217 )
2019
9
Human leukocyte antigen class II expression is a good prognostic factor of adult T-cell leukemia/lymphoma. ( 30630986 )
2019
10
Association of high levels of plasma OX40 with acute adult T-cell leukemia. ( 30652238 )
2019
11
Granuloma With an Underlying Lymphoma: A Diagnostic Challenge and a Wider Histologic Spectrum Including Adult T-Cell Leukemia/Lymphoma. ( 30653030 )
2019
12
Prognostic impact of soluble interleukin-2 receptor level profiling in smoldering type adult T-cell leukemia-lymphoma. ( 30656718 )
2019
13
Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. ( 30657736 )
2019
14
VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis. ( 30664725 )
2019
15
Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: A hope for disease-preventive therapy. ( 30666755 )
2019
16
Clinical features at transformation in adult T-cell leukemia-lymphoma with smoldering and chronic types. ( 30680667 )
2019
17
JSH Practical Guidelines for Hematological Malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia-lymphoma. ( 30701465 )
2019
18
Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma. ( 30740787 )
2019
19
Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. ( 30773707 )
2019
20
Hypericin-photodynamic therapy inhibits the growth of adult T-cell leukemia cells through induction of apoptosis and suppression of viral transcription. ( 30782173 )
2019
21
Cells of adult T-cell leukemia evade HTLV-1 Tax/NF-κB hyperactivation-induced senescence. ( 30787019 )
2019
22
Adult T-cell leukemia/lymphoma with conjunctival chemosis from infiltration and raised intraocular pressure. ( 30851797 )
2019
23
PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma. ( 30862694 )
2019
24
Crusted (Norwegian) scabies as a strong marker of adult T-cell leukemia/lymphoma in HTLV-1 infection. ( 30899475 )
2019
25
A Case of Adult T-Cell Leukemia/Lymphoma Complicated with Bilateral Chylothorax. ( 30911425 )
2019
26
Activation of Notch1 signaling by HTLV-1 Tax promotes proliferation of adult T-cell leukemia cells. ( 30914196 )
2019
27
Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma. ( 30981611 )
2019
28
Lymphomatous Variant of Adult T-cell Leukemia/Lymphoma. ( 30983618 )
2019
29
Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018). ( 30996180 )
2019
30
Molecular remissions are observed in chronic adult T cell leukemia/lymphoma in patients treated with mogamulizumab. ( 31004017 )
2019
31
Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy. ( 31016134 )
2019
32
A novel mouse model of adult T-cell leukemia cell invasion into the spinal cord. ( 31016289 )
2019
33
Therapeutic Efficacy of Etretinate on Cutaneous-type Adult T-cell Leukemia-Lymphoma. ( 31017247 )
2019
34
Mogamulizumab treatment elicits autoantibodies attacking the skin in patients with adult T cell leukemia-lymphoma. ( 31018922 )
2019
35
Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all? ( 31040231 )
2019
36
Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations. ( 31040232 )
2019
37
Response to the comment: "Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations". ( 31040233 )
2019
38
Flower cells of tropical descent: a challenging case of adult T-cell leukemia/lymphoma. ( 31041884 )
2019
39
RNA sequencing identifies clonal structure of T-cell repertoires in patients with adult T-cell leukemia/lymphoma. ( 31069115 )
2019
40
Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma. ( 31104532 )
2019
41
Smoldering type adult T-cell leukemia/lymphoma effectively treated with mogamulizumab (anti-CC chemokine receptor 4 monoclonal antibody)-A case report. ( 31110745 )
2019
42
Impact of pretransplant central nervous system invasion in patients with aggressive adult T-cell leukemia lymphoma. ( 29899570 )
2019
43
Cytotoxic T-lymphocyte-associated antigen 4-positive aggressive adult T cell leukemia/lymphoma. ( 29978285 )
2019
44
Clinical features and human T-cell leukemia virus type-1 (HTLV-1) proviral load in HTLV-1-positive patients with rheumatoid arthritis: Baseline data in a single center cohort study. ( 30938551 )
2019
45
Case of cryptococcal choroiditis in adult with T-cell leukemia/lymphoma. ( 30057340 )
2019
46
Hemophagocytic Lymphohistiocytosis Associated with Natural T-cell Leukemia. ( 31058001 )
2019
47
Dendritic Cells Promote the Spread of Human T-Cell Leukemia Virus Type 1 via Bidirectional Interactions with CD4+ T Cells. ( 30048652 )
2019
48
Multiplex Droplet Digital PCR Assay for Quantification of Human T-Cell Leukemia Virus Type 1 Subtype c DNA Proviral Load and T Cells from Blood and Respiratory Exudates Sampled in a Remote Setting. ( 30518541 )
2019
49
Risk of Human T-Cell Leukemia Virus Type 1 Infection in Kidney Transplantation. ( 30650320 )
2019
50
Human T cell leukemia virus type 1 and Zika virus: tale of two reemerging viruses with neuropathological sequelae of public health concern. ( 30693421 )
2019

Variations for T-Cell Leukemia

Expression for T-Cell Leukemia

Search GEO for disease gene expression data for T-Cell Leukemia.

Pathways for T-Cell Leukemia

Pathways related to T-Cell Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 ATF4 CREB1 IL2 IL2RA TCL1A TCL1B
2 11.69 ATF4 CREB1 IL2 IL2RA SLC2A1
3 11.51 ATF4 CREB1 SLC2A1
4 11.06 ATF4 CREB1 SLC2A1
5 10.85 MIR106A MIR19B2 MIR20B MIR92A2

GO Terms for T-Cell Leukemia

Cellular components related to T-Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.35 MIR106A MIR143 MIR19B2 MIR20B MIR92A2
2 ATF4-CREB1 transcription factor complex GO:1990589 8.62 ATF4 CREB1

Biological processes related to T-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.99 ATF4 CREB1 IL2 LMO1 TAL1 TLX1
2 negative regulation of angiogenesis GO:0016525 9.63 MIR143 MIR20B MIR92A2
3 negative regulation of inflammatory response GO:0050728 9.54 IL2 IL2RA MIR92A2
4 miRNA mediated inhibition of translation GO:0035278 9.5 MIR106A MIR19B2 MIR92A2
5 regulation of hematopoietic stem cell differentiation GO:1902036 9.49 LMO1 TAL1
6 positive regulation of T cell differentiation GO:0045582 9.48 IL2 IL2RA
7 negative regulation of cholesterol efflux GO:0090370 9.43 MIR130B MIR19B2
8 gene silencing by miRNA GO:0035195 9.43 MIR106A MIR130B MIR143 MIR19B2 MIR20B MIR92A2
9 regulation of regulatory T cell differentiation GO:0045589 9.4 IL2 IL2RA
10 interleukin-2-mediated signaling pathway GO:0038110 9.26 IL2 IL2RA
11 negative regulation of lymphocyte proliferation GO:0050672 9.16 IL2 IL2RA
12 regulation of T cell homeostatic proliferation GO:0046013 8.8 IL2 IL2RA LMO1

Molecular functions related to T-Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 9.13 ATF4 CREB1 TAL1
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR106A MIR130B MIR143 MIR19B2 MIR20B MIR92A2

Sources for T-Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....